Transcript www.bloodjournal.org

A phase 1 clinical trial of long-term, low-dose treatment of
WHIM syndrome with the CXCR4 antagonist plerixafor
by David H. McDermott, Qian Liu, Daniel Velez, Lizbeeth Lopez, Sandra AnayaO’Brien, Jean Ulrick, Nana Kwatemaa, Judy Starling, Thomas A. Fleisher, Debra A.
Long Priel, Melissa A. Merideth, Robert L. Giuntoli, Moses O. Evbuomwan, Patricia
Littel, Martha M. Marquesen, Dianne Hilligoss, Rosamma DeCastro, George J.
Grimes, Samuel T. Hwang, Stefania Pittaluga, Katherine R. Calvo, Pamela Stratton,
Edward W. Cowen, Douglas B. Kuhns, Harry L. Malech, and Philip M. Murphy
Blood
Volume 123(15):2308-2316
April 10, 2014
©2014 by American Society of Hematology
Leukocytes are mobilized to the blood by twice daily administration of plerixafor in WHIM
syndrome patients: early phase.
David H. McDermott et al. Blood 2014;123:2308-2316
©2014 by American Society of Hematology
Leukocyte dynamics in response to plerixafor in WHIM syndrome patients are durable over time.
David H. McDermott et al. Blood 2014;123:2308-2316
©2014 by American Society of Hematology
Plerixafor treatment durably maintains peak and trough leukocyte subset levels above baseline
for at least 6 months.
David H. McDermott et al. Blood 2014;123:2308-2316
©2014 by American Society of Hematology
Chronic plerixafor treatment has prolonged effects on blood leukocyte levels in patients with
WHIM syndrome.
David H. McDermott et al. Blood 2014;123:2308-2316
©2014 by American Society of Hematology
Plerixafor may reduce infection incidence in patients with WHIM syndrome.
David H. McDermott et al. Blood 2014;123:2308-2316
©2014 by American Society of Hematology
Plerixafor with imiquimod may improve warts in patients with WHIM syndrome.
David H. McDermott et al. Blood 2014;123:2308-2316
©2014 by American Society of Hematology